Andreas Argyrides
Stock Analyst at Oppenheimer
(4.38)
# 351
Out of 5,239 analysts
119
Total ratings
51.85%
Success rate
19.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Outperform | $10 | $5.18 | +93.05% | 1 | Mar 16, 2026 | |
| LQDA Liquidia | Maintains: Underperform | $16 → $19 | $56.60 | -66.43% | 8 | Mar 12, 2026 | |
| GOSS Gossamer Bio | Maintains: Outperform | $12 → $3 | $0.34 | +780.80% | 9 | Mar 5, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $581.74 | +3.14% | 2 | Feb 26, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $30 → $35 | $18.19 | +92.41% | 15 | Feb 24, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $22.69 | +85.10% | 1 | Jan 22, 2026 | |
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $18.37 | +117.75% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $5.08 | +77.17% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $11.65 | +131.76% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $61.35 | +87.45% | 2 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $21 | $4.13 | +408.47% | 2 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $29 | $11.84 | +144.93% | 2 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $33 | $3.12 | +957.69% | 2 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $3.28 | +357.32% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $20 | $5.68 | +252.11% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $30.15 | +102.32% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $4.16 | +68.27% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $2.43 | +23.46% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $1.10 | +263.64% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $11.22 | +702.14% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $1.60 | +462.50% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $237.65 | -23.84% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $8.63 | +120.16% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $30.41 | -4.64% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $10.24 | +105.08% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $19.13 | +1,070.94% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $22.84 | +149.56% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $70 | $11.90 | +488.24% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $52.88 | +32.38% | 6 | Aug 1, 2023 |
Opus Genetics
Mar 16, 2026
Initiates: Outperform
Price Target: $10
Current: $5.18
Upside: +93.05%
Liquidia
Mar 12, 2026
Maintains: Underperform
Price Target: $16 → $19
Current: $56.60
Upside: -66.43%
Gossamer Bio
Mar 5, 2026
Maintains: Outperform
Price Target: $12 → $3
Current: $0.34
Upside: +780.80%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $575 → $600
Current: $581.74
Upside: +3.14%
MoonLake Immunotherapeutics
Feb 24, 2026
Maintains: Outperform
Price Target: $30 → $35
Current: $18.19
Upside: +92.41%
Evommune
Jan 22, 2026
Initiates: Outperform
Price Target: $42
Current: $22.69
Upside: +85.10%
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $18.37
Upside: +117.75%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $5.08
Upside: +77.17%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $11.65
Upside: +131.76%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $61.35
Upside: +87.45%
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $4.13
Upside: +408.47%
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $11.84
Upside: +144.93%
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $3.12
Upside: +957.69%
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $3.28
Upside: +357.32%
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.68
Upside: +252.11%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $30.15
Upside: +102.32%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $4.16
Upside: +68.27%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $2.43
Upside: +23.46%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $1.10
Upside: +263.64%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $11.22
Upside: +702.14%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.60
Upside: +462.50%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $237.65
Upside: -23.84%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $8.63
Upside: +120.16%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $30.41
Upside: -4.64%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $10.24
Upside: +105.08%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $19.13
Upside: +1,070.94%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $22.84
Upside: +149.56%
Oct 10, 2023
Maintains: Outperform
Price Target: $50 → $70
Current: $11.90
Upside: +488.24%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $52.88
Upside: +32.38%